The antiemetics industry plays a crucial role in the healthcare sector by providing medications that help alleviate nausea and vomiting. Understanding key statistics and trends in this industry is essential for healthcare professionals, researchers, and policymakers to make informed decisions and advancements in patient care. In this blog post, we will delve into the latest statistics and insights shaping the antiemetics industry.
The Latest Antiemetics Industry Statistics Explained
The global Antiemetics Market size was valued at USD 5.1 billion in 2020.
The statistic “The global Antiemetics Market size was valued at USD 5.1 billion in 2020” indicates the total monetary value of the market for antiemetic medications worldwide in the year 2020. Antiemetics are drugs used to prevent or treat nausea and vomiting, commonly administered to patients undergoing chemotherapy, surgery, or experiencing motion sickness. The market size of USD 5.1 billion suggests a significant demand for antiemetic medications on a global scale, reflecting the prevalence of conditions that necessitate their use and the ongoing research and development efforts within the pharmaceutical industry to address such needs. This statistic serves as a reflection of the economic significance and growth potential of the global antiemetics market.
It is expected that the antiemetic market will grow at a CAGR of 4.5% from 2020 to 2027.
This statistic indicates that the antiemetic market, which focuses on products used to prevent or treat nausea and vomiting, is projected to experience a Compound Annual Growth Rate (CAGR) of 4.5% from 2020 to 2027. This means that the market size for antiemetic medications is expected to increase by 4.5% on average each year during this period. This growth rate suggests a positive trend in demand for antiemetic products, possibly driven by factors such as an aging population, an increase in chemotherapy treatments, or the development of new and more effective antiemetic drugs. Pharmaceutical companies and healthcare professionals may use this information to anticipate and plan for shifts in market dynamics within the antiemetic sector.
The North America region had the largest market share of 39.7% in 2020 in the antiemetic industry.
The statistic indicates that in 2020, the antiemetic industry in North America held the largest market share of 39.7% compared to other regions. This suggests that a significant portion of antiemetic products were consumed or sold in North America relative to other regions around the world during that year. This data is crucial for understanding the distribution and consumption patterns of antiemetic drugs in different regions and can be used by companies to strategize their marketing, production, and distribution efforts to maximize their market presence and sales in North America.
The 5-HT3 receptor antagonists segment held the largest revenue share of more than 30.0% in 2020.
The statistic ‘The 5-HT3 receptor antagonists segment held the largest revenue share of more than 30.0% in 2020’ indicates that, among all the different types of medications or treatments included in the market analysis, the category of 5-HT3 receptor antagonists generated the highest revenue compared to other segments in 2020. Specifically, this segment accounted for more than 30.0% of the total revenue in the market during that year. This suggests that there is a significant demand for 5-HT3 receptor antagonists, possibly due to their efficacy, popularity, or other factors, making them a key player in shaping the market trends and dynamics in 2020.
The cannabis-based antiemetics are projected to witness the fastest growth rate of over 14.0% from 2022 to 2027.
This statistic indicates that cannabis-based antiemetics, which are medications used to alleviate nausea and vomiting, are expected to experience a rapid increase in demand over the five-year period from 2022 to 2027. The projected growth rate of over 14.0% suggests that these specific products are likely to outpace other antiemetic medications in terms of market expansion during this time frame. This strong growth trajectory may be driven by various factors such as increasing acceptance and legalization of cannabis for medical purposes, growing awareness of the therapeutic properties of cannabis in managing nausea, and potentially favorable clinical outcomes compared to traditional antiemetic drugs. Consequently, this statistic highlights a notable trend towards the adoption and utilization of cannabis-based antiemetics in the healthcare industry.
The chemotherapy-induced nausea and vomiting segment held the largest share of the antiemetics market in 2020.
In 2020, the segment of chemotherapy-induced nausea and vomiting held the largest share of the antiemetics market. This statistic indicates that a significant portion of the market for medications that prevent and treat nausea and vomiting is attributed to individuals undergoing chemotherapy treatment. Chemotherapy-induced nausea and vomiting can be a common and distressing side effect of cancer treatment, underscoring the importance and prevalence of this market segment. This information suggests that pharmaceutical companies and healthcare providers may focus their efforts on developing and providing effective antiemetic drugs specifically tailored to address the needs of patients undergoing chemotherapy.
The postoperative and post-dissection segment is expected to witness the fastest growth over the forecast period.
The statistic “The postoperative and post-dissection segment is expected to witness the fastest growth over the forecast period” suggests that within a particular industry or market, the segment related to postoperative and post-dissection processes is projected to experience the most rapid expansion compared to other segments in the upcoming period. This growth can be attributed to various factors such as advancements in technology, increasing demand for related products or services, evolving surgical techniques, or changing demographics. Companies operating in this segment might see increased revenue opportunities and market share as a result of this projected growth trend. It is important for stakeholders to closely monitor and capitalize on the opportunities presented by this fast-growing segment to stay competitive and maximize profitability.
Hospitals dominated the market with a share of 46.7% in 2020.
This statistic indicates that hospitals held a significant portion of the market in 2020, accounting for 46.7% of the total market share. This suggests that hospitals were the dominant players in the industry, likely providing a wide range of healthcare services to a substantial portion of the population. The high market share held by hospitals may reflect their importance as key providers of healthcare services and their widespread presence in the market compared to other healthcare providers. The statistic highlights the competitive landscape and the significant role that hospitals play in the healthcare industry.
Prochlorperazine was the leading segment in 2020 and was valued at USD 653.9 million.
The statistic indicates that in the year 2020, the segment of Prochlorperazine held the highest market value within its industry, estimated at USD 653.9 million. This suggests that Prochlorperazine, a type of medication commonly used to treat nausea and vomiting, experienced significant demand and consumption compared to other segments or competitors in the market during that year. The high value reflects the perceived effectiveness and widespread use of Prochlorperazine, likely due to its proven efficacy and affordability, positioning it as the market leader in its category.
North America was followed by Europe, which captured a revenue share of 28.3% in 2020.
The statistic indicates that in 2020, Europe had the second-highest revenue share after North America, with Europe capturing a share of 28.3%. This suggests that Europe played a significant role in the total revenue generated, trailing closely behind North America. The data implies that Europe’s economic activities, industries, and consumer markets contributed substantially to the overall revenue in the specified context, highlighting the region’s importance in the financial landscape for that particular period. It also hints at the relative strength and competitiveness of Europe’s market compared to other regions, further underlining its significance in terms of generating revenue.
The Asia Pacific region is anticipated to witness the fastest CAGR over the forecast period.
The statement “The Asia Pacific region is anticipated to witness the fastest Compound Annual Growth Rate (CAGR) over the forecast period” suggests that the Asia Pacific region is expected to experience a higher rate of growth compared to other regions during the specified time frame. This statistic indicates that the economies within the Asia Pacific region are likely to expand at a quicker pace, leading to increased market opportunities, investments, and overall economic prosperity. Stakeholders and investors may find this information valuable as it highlights the region’s potential for higher returns and growth prospects in the future.
In 2020, Alkermes earned a revenue of USD 52.3 million from the drug Aristada, which is an injectable medication.
The statistic indicates that in 2020, Alkermes, a pharmaceutical company, generated a revenue of USD 52.3 million from the sales of the drug Aristada, which is an injectable medication. This revenue figure suggests that Aristada plays a significant role in Alkermes’ overall financial performance for the year. The success of Aristada in generating revenue highlights its popularity or effectiveness in the market, as well as the importance of injectable medications within the company’s product portfolio. This information is valuable for stakeholders, investors, and analysts in understanding Alkermes’ revenue sources and the impact of its drug products on the company’s financial performance.
The pharming group earned a revenue of USD 185.6 million in 2020 from its drug Ruconest which is an injectable medication.
The statistic indicates that the pharming group generated a total revenue of USD 185.6 million in 2020 from the sales of Ruconest, an injectable medication. This revenue figure represents the amount of money earned from the sales of Ruconest during the specified time period. The revenue generated from this drug highlights its commercial success and market demand, potentially indicating its effectiveness in treating the targeted medical condition. The figure also reflects the financial performance of the pharming group specifically attributed to Ruconest sales in 2020.
The pharmaceutical segment held the largest share in the antiemetics market in 2020.
The statistic that the pharmaceutical segment held the largest share in the antiemetics market in 2020 indicates that pharmaceutical companies specializing in antiemetic medications dominated the market compared to other types of companies such as biotech or healthcare providers. This suggests that pharmaceutical companies were the primary providers of antiemetic drugs to address conditions such as nausea and vomiting. This could be attributed to factors such as their research and development efforts, proprietary drug formulations, and established distribution networks that helped them capture a significant portion of the market demand for antiemetics in 2020.
Japan held a significant share in the Asia Pacific market due to the presence of key players such as Otsuka and Takeda Pharmaceutical Company Limited.
The statistic suggests that Japan has a dominant position in the Asia Pacific market, largely attributed to the presence and influence of major companies like Otsuka and Takeda Pharmaceutical Company Limited. These key players have a significant market share and are likely to play a crucial role in shaping the pharmaceutical industry’s landscape in the region. Their strong presence, established reputation, and innovative products contribute to Japan’s prominence in the market, positioning the country as a major player in the pharmaceutical sector within the Asia Pacific region.
The retail pharmacy segment accounted for the largest revenue share and is anticipated to witness substantial growth over the forecast period.
This statistic suggests that the retail pharmacy sector generated the highest revenue among all segments and is expected to experience significant growth in the upcoming period. The retail pharmacy industry is likely performing well due to factors such as increasing demand for healthcare products and services, the convenience of accessible locations for consumers, and various healthcare reforms driving more people towards seeking healthcare services. The anticipated substantial growth indicates a positive outlook for the retail pharmacy sector, showcasing potential opportunities for expansion, investment, and market development in the future.
Online pharmacies are expected to witness the fastest growth rate over the forecast period.
The statistic “Online pharmacies are expected to witness the fastest growth rate over the forecast period” indicates that within the pharmaceutical industry, online pharmacies are projected to experience the most rapid increase in sales or market share in the upcoming period of analysis. This suggests that the demand for pharmaceutical products through online platforms is anticipated to escalate at a higher rate compared to traditional brick-and-mortar pharmacies. Factors contributing to this trend may include the convenience of purchasing medications online, the increasing prevalence of e-commerce, advancements in technology facilitating e-pharmacy operations, and changing consumer preferences towards digital shopping experiences. The implication of this statistic is that online pharmacies are positioned for significant growth opportunities, leading stakeholders in the healthcare and pharmaceutical sectors to focus on adapting their business models to capitalize on this emerging trend.
The OTC segment is expected to expand at a significant CAGR over the forecast period.
This statistic suggests that the over-the-counter (OTC) segment, referring to the market for non-prescription drugs and health products, is projected to experience substantial growth over a specified period of time. The Compound Annual Growth Rate (CAGR) indicates the annualized rate of growth that the OTC segment is expected to achieve over the forecast period. This forecast implies that consumer demand for over-the-counter products is anticipated to increase steadily, potentially driven by factors such as consumer preferences for self-care options, expanding accessibility to healthcare products, and advancements in the OTC industry. The significant CAGR projection suggests opportunities for market expansion, innovation, and investment within the OTC segment in the coming years.
The clinical guidelines by the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC) recommend the use of 5-HT3 receptor antagonists, NK-1 receptor antagonists, and dexamethasone as Antiemetics for patients undergoing highly emetogenic chemotherapy.
The statistic highlights the clinical guidelines provided by the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC), which advocate for the use of specific antiemetic medications for patients undergoing highly emetogenic chemotherapy. Specifically, the recommended antiemetics include 5-HT3 receptor antagonists, NK-1 receptor antagonists, and dexamethasone. These medications target different biological pathways involved in preventing chemotherapy-induced nausea and vomiting, which are common and distressing side effects of highly emetogenic chemotherapy regimens. By following these evidence-based guidelines and utilizing the recommended antiemetics, healthcare providers can help improve the quality of life and treatment experience for cancer patients undergoing chemotherapy.
Diabetes affects approximately 422 million people worldwide (WHO, 2016) and is therefore a significant target for antiemetic manufacturers due to the comorbidity of nausea and vomiting with diabetes.
The statistic states that approximately 422 million people worldwide are affected by diabetes, according to the World Health Organization (WHO) in 2016. This highlights the staggering prevalence of diabetes globally and signifies the significant public health burden associated with the disease. Moreover, the statement suggests that diabetes is a significant target for antiemetic manufacturers because nausea and vomiting commonly coexist with diabetes as comorbid symptoms. Given the large number of individuals suffering from diabetes and experiencing associated symptoms such as nausea and vomiting, developing effective antiemetic medications could potentially address a pressing need in improving the quality of life for diabetic patients and managing their symptoms more effectively.
Conclusion
The antiemetics industry statistics provide valuable insights into the market size, growth trends, and competitive landscape of this important sector. By examining these statistics, stakeholders can make informed decisions and strategic plans to address the challenges and opportunities in the antiemetics market.
References
0. – https://www.www.grandviewresearch.com
1. – https://www.www.bizjournals.com
2. – https://www.www.nasdaq.com
